Non-clinical Polymerase Chain Reaction (PCR) Market - Databook 2025 to 2034

The global non-clinical polymerase chain reaction (PCR) market size accounted for USD 12.11 billion in 2024 and is predicted to touch around USD 17.37 billion by 2034, growing at a CAGR of 3.8% from 2025 to 2034.

Highlights of the Non-clinical Polymerase Chain Reaction (PCR) Market

• North America dominated the non-clinical polymerase chain reaction (PCR) market in 2024.
• Asia-Pacific is expected to show the fastest growth in the forecasted period of 2025-2034.
• By application area, the basic research segment accounted for a considerable share of the market in 2024.
• By application area, the pharmaceutical research segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By product type, the reagents & consumables segment registered its dominance over the market in 2024.
• By product type, the instrumentation segment is projected to experience the highest growth rate in the market between 2025 and 2034.
• By end-use, the pharmaceutical & biotechnology companies segment held the largest market share in 2024.
• By end-use, the academic & research institutions segment is growing at the fastest rate during the predicted timeframe.

Industry Valuation and Growth Rate Projection

Polymerase chain reaction refers to a laboratory technique that can amplify a specific segment of DNA a number of times as per the requirement. The applications of PCR clinically and non-clinically are different. The non-clinical polymerase chain reaction (PCR) market is rapidly expanding globally due to its wide range of non-clinical applications. Non-clinical applications include food safety, animal health, agriculture, environmental monitoring, and laboratories in general.

The PCR technique has the potential and capability to allow for diagnoses of plant and animal diseases, answering concerns of microbes in foods, and analyzing nucleoproteins of organisms and studying organisms' genes. The factors due to the market boom are - expansion, including ensuring food safety, fresh drinking water, and looking for more advanced tools for research.

There are also modern advances in PCR machines that can give you quicker and more accurate results. The advancement in automation has occurred in parallel with more advanced kits that are being used for the acquisition of input answers, being used by some of the market leaders. Along with this growth, there seems to be greater utilization for research/educational institutions as well. In fact, with more countries, through advances in technology, starting to understand the non-clinical polymerase chain reaction (PCR) market, I can really see great growth in the future.

Non-clinical Polymerase Chain Reaction (PCR) Market: Stats and Figures

• According to the CDC, congenital heart defects are one of the most common birth defects in the United States, affecting nearly 1% of births each year.

How AI has Benefited the Non-clinical Polymerase Chain Reaction (PCR) Market

• User-friendly: AI programs are able to instruct the lab worker, as a novice might be working with PCR machines, on what the next step in the process is.
• Saves time and money: AI diminishes the number of tests necessary by providing better accuracy the first time around and saves the costs incurred for materials and time spent testing for accuracy in a view duplicative test process.
• Reduced time: Artificial intelligence will enable PCR platforms to become faster, because its technology can read and analyze DNA information in less time. Therefore, scientists and laboratories will get results faster than they did before.
• Improved accuracy: In some cases, human error may occur when scientists are reading test results, and AI is able to detect subtleties in the DNA and patterns in the DNA that would otherwise be missed by humans; thus, it will improve the accuracy of the test results.

Industry Leader Announcements

• Dr. Nick Ashton, Senior Director, Biomarker Program at Banner Sun Health Research Institute, said:

Advancements in Research Use Only (RUO) assays for neurodegenerative diseases mark a transformative step in the field, offering precise tools to unravel disease mechanisms. These assays enable researchers to detect and quantify biomarkers with exceptional sensitivity and specificity, facilitating a deeper understanding of conditions such as Alzheimer's disease.”

Geographical Insights

North America

North America dominated the non-clinical polymerase chain reaction (PCR) market in 2024. The leading region for non-clinical PCR is North America. Numerous research labs, universities, and food testing labs in the U.S. and Canada conduct PCR testing almost on a daily basis, and the U.S. uses it heavily to test for food safety and animal disease research. The Centers for Disease Control and Prevention and the U.S. Department of Agriculture publish using PCR in a non-clinical context. Additionally, North America houses firms that are market leaders in PCR, such as Thermo Fisher Scientific and Bio-Rad Laboratories, creating cutting-edge biomedical tools in this area. With well-funded programs and top-tier laboratories, North America will continue to excel in this market.

Asia-Pacific

Asia-Pacific is anticipated to be the fastest-growing market in the forecasted period of 2025-2034. Asia-Pacific is a primary market that is growing rapidly in the non-clinical polymerase chain reaction (PCR) market. There has been a significant uptake in non-clinical PCR tests being performed across Asia, specifically in China, India, Japan, and South Korea, in things like PCR for new food safety studies, agriculture, and research. In India, some research uses PCR to check for germs in crops and milk, while in China, it is now used to monitor water and air pollution.

Research funders and governments are increasing spending on scientists and lab equipment; the number of students going into research is higher than it has ever been; and there are local manufacturers producing lower-cost PCR kits. There is a growing demand for clean food, improved agricultural practices, and the need for solid laboratory capacity, so we anticipate the Asia-Pacific non-clinical PCR market will continue to experience rapid growth and affect people's everyday lives.

Recent Developments

• In January 2025, Beckman Coulter Diagnostics, a global leader in advanced diagnostics, announced the launch of new Research Use Only (RUO) blood-based biomarker immunoassays, which are designed for assessing p-Tau217, GFAP, NfL, and APOE ε4 biomarkers for advancing neurodegenerative diseases research.

Competitive Landscape

The non-clinical PCR market is highly competitive. Some of the key players in the market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Bioer Technology Co., Ltd., Bio-Rad Laboratories, Inc., Eppendorf AG, Promega Corporation, Qiagen N.V., Roche Diagnostics, and Takara Bio USA, Inc.

The non-clinical PCR market is dominated by several companies but the companies that are renowned for their contribution to the market are listed below:

• Company Name: Thermo Fisher Scientific Inc.
• Year of Incorporation: 1956
• Headquarters: Massachusetts, USA.

Thermo Fisher Scientific Inc. is a leading global life science and clinical research company with operations involved in supplying analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical, and biotechnology services. The company recorded a revenue of US$ 42.879 billion in the year 2024.

• Company Name: Agilent Technologies Inc.
• Year of Incorporation: 1999
• Headquarters: Santa Clara, California

Agilent Technologies Inc. is an American multinational supplier of instruments, software, services, and consumables for laboratories. It was established in 1999 and produced optics (LED, laser), semiconductors, EDA software, and test and measurement equipment for electronics, and then shifted towards pharmaceuticals in 2014. The company recorded a revenue of US$6.51 billion in 2024.

• Company Name: Bioer Technology Co.
• Year of Incorporation: 2002
• Headquarters: Hangzhou, China

Bioer Technology Co. is a leading supplier of life science and medical diagnostic products in China. The company specializes in research and development, manufacture, and sales of molecular detection serial products.